RxDoctor Payments Data

Thomas Reske, MD

Internal Medicine · Boston, MANPI 1669545802

Payments from drug & device makers

$18,293in general payments, 2019–2025

Across 55 payments — averaging $332.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$10K
  • Partner Therapeutics, Inc.$4K
  • Exelixis Inc.$2K
  • Daiichi Sankyo Inc.$1K
  • Stryker$154
  • Tempus AI, Inc$136
  • plus $698 from 13 others

What the payments were for

  • Consulting fees$3,65047%
  • Speaking & faculty fees$2,40031%
  • Travel & lodging$5016%
  • Food & beverage$1,29617%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,293 in reported general payments places this provider in the 95th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$14,463
Medicare patients
66
Services billed
160

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CopaxoneGlatiramer Acetate13$80,098
NuplazidPimavanserin Tartrate23$57,177
EliquisApixaban153$49,402
MyrbetriqMirabegron45$10,670
RytaryCarbidopa/Levodopa20$5,054
Mirtazapine61$3,345
Levothyroxine Sodium127$2,207
Amiodarone Hcl25$2,012
Quetiapine Fumarate80$1,711
Memantine Hcl49$1,609
Donepezil Hcl73$1,565
Sertraline Hcl71$1,517
Atorvastatin Calcium91$1,513
Metoprolol Succinate85$1,394
Amlodipine Besylate71$1,305

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$111$49,402153 claims
Astellas Pharma US IncMyrbetriq$33$10,67045 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →